Showing results (401-410 of 425) with videos related to

Sort By:
Pageof 43
The New England Journal of Medicine|June 6, 2017
Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast CancerGunter von Minckwitz, Marion Procter, Evandro de Azambuja, et al.
NIHR Open Research|October 25, 2023
Using the AR-V7 biomarker to determine treatment in metastatic castrate resistant prostate cancer, a feasibility randomised control trial, conclusions from the VARIANT trialPaul Gravestock, Emma Clark, Miranda Morton, et al.
Brain Sciences|October 3, 2020
A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral AssessmentsDejan B Budimirovic, Annette Schlageter, Stela Filipovic-Sadic, et al.
Blood|March 2, 2026
Fixed-duration VenO vs FCR/BR in fit patients with untreated CLL: primary analysis of the phase 3 CRISTALLO trialJeff P Sharman, Luca Laurenti, Emmanuelle France Ferrant, et al.
BMJ Open|August 19, 2021
Improving uptake of Fracture Prevention drug treatments: a protocol for Development of a consultation intervention (iFraP-D)Zoe Paskins, Laurna Bullock, Fay Crawford-Manning, et al.
American Journal of Human Genetics|January 17, 2003
Expansion of the fragile X CGG repeat in females with premutation or intermediate allelesSarah L Nolin, W Ted Brown, Anne Glicksman, et al.
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
NPJ Microgravity|March 6, 2024
Microgravity effects on nonequilibrium melt processing of neodymium titanate: thermophysical properties, atomic structure, glass formation and crystallizationStephen K Wilke, Abdulrahman Al-Rubkhi, Chihiro Koyama, et al.
Plos One|May 9, 2012
Abnormal intracellular accumulation and extracellular Aβ deposition in idiopathic and Dup15q11.2-q13 autism spectrum disordersJerzy Wegiel, Janusz Frackowiak, Bozena Mazur-Kolecka, et al.
European Journal of Cancer (Oxford, England : 1990)|March 21, 2022
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trialRichard D Gelber, Xin V Wang, Bernard F Cole, et al.
Pageof 43